Trunzo Roberta, Santacroce Rosa, Shen Nan, Jung-Klawitter Sabine, Leccese Angelica, De Girolamo Giuseppe, Margaglione Maurizio, Blau Nenad
Genetica Medica, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Foggia, Italy.
Genetica Medica, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Foggia, Italy.
Gene. 2016 Dec 5;594(1):138-143. doi: 10.1016/j.gene.2016.09.015. Epub 2016 Sep 13.
Hyperphenylalaninemias (HPAs) are genetic diseases predominantly caused by a wide range of variants in the phenylalanine hydroxylase (PAH) gene. In vitro expression analysis of PAH variants offers the opportunity to elucidate the molecular mechanisms involved in HPAs and to clarify whether a disease-associated variant is genuinely pathogenic, while investigating the severity of a metabolic phenotype, and determining how a variant exerts its deleterious effects on the PAH enzyme. To study the effects of gene variants on PAH activity, we investigated eight variants: c.611A>G (p.Y204C), c.635T>C (p.L212P), c.746T>C (p.L249P), c.745C>T (p.L249F), c.809G>A (p.R270K), c.782G>C (p.R261P), c.587C>A (p.S196Y) and c.1139C>T (p.T380M), associated with different phenotypic groups. Transient expression of mutant full-length cDNAs in COS-7 cells yielded PAH proteins with PAH activity levels between 7% and 51% compared to the wild-type enzyme. With one exception (p.Y204C, which had no significant impact on PAH function), lower PAH activity was associated with a more severe phenotype (e.g. p.L249P with 7% PAH activity, 100% of classic PKU and no BH responsiveness), while higher activity correlated with milder phenotypes (e.g. p.T380M with 28% PAH activity, 97% of mild HPA and 83% of BH responsiveness). The results of the in vitro residual PAH activity have major implications, both for our understanding of genotype-phenotype correlations, and thereby existing inconsistencies, but also for the elucidation of the molecular basis of tetrahydrobiopterin (BH) responsiveness.
高苯丙氨酸血症(HPAs)是主要由苯丙氨酸羟化酶(PAH)基因中广泛存在的多种变异引起的遗传性疾病。对PAH变异体进行体外表达分析,为阐明HPAs所涉及的分子机制、明确疾病相关变异体是否真正具有致病性提供了契机,同时还能研究代谢表型的严重程度,并确定变异体如何对PAH酶产生有害影响。为了研究基因变异对PAH活性的影响,我们调查了八个与不同表型组相关的变异体:c.611A>G(p.Y204C)、c.635T>C(p.L212P)、c.746T>C(p.L249P)、c.745C>T(p.L249F)、c.809G>A(p.R270K)、c.782G>C(p.R261P)、c.587C>A(p.S196Y)和c.1139C>T(p.T380M)。与野生型酶相比,在COS-7细胞中瞬时表达突变全长cDNA产生的PAH蛋白,其PAH活性水平在7%至51%之间。除了一个例外(p.Y204C对PAH功能没有显著影响),较低的PAH活性与更严重的表型相关(例如p.L249P的PAH活性为7%,100%为经典苯丙酮尿症且对四氢生物蝶呤无反应),而较高的活性与较温和的表型相关(例如p.T380M的PAH活性为28%,97%为轻度HPA且83%对四氢生物蝶呤有反应)。体外残余PAH活性的结果不仅对我们理解基因型-表型相关性以及现存的不一致性具有重要意义,而且对阐明四氢生物蝶呤(BH)反应性的分子基础也具有重要意义。